CELL FREE DNA-BASED PREDICTION OF PROGNOSIS FOR PATIENTS ON VENO-ARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Translational Medicine

Background:

• Elevated cell-free DNA (cfDNA) is observed in patients undergoing extracorporeal membrane oxygenation (ECMO).
• The clinical significance of cfDNA in ECMO patients remains unclear.
• Predictive markers for prognosis and complications in ECMO are needed.

Purpose of the Study:

• To develop a predictive model for ECMO patient mortality using cfDNA.
• To evaluate cfDNA's role in predicting limb ischemia and bleeding/thromboembolic events.
• To clarify the clinical relevance of cfDNA in venoarterial (VA)-ECMO support.

Main Methods:

• Retrospective analysis of 133 adult patients receiving VA-ECMO for cardiogenic shock.
• Development of a logistic regression model incorporating cfDNA, mean arterial pressure (MAP), and lactate levels.
• Validation of the model using a separate cohort of 27 patients and analysis of complication associations using restricted cubic spline and ROC analyses.

Main Results:

• A predictive model combining cfDNA, pre-ECMO MAP, and post-ECMO lactate demonstrated good performance (AUC 0.768 in derivation, 0.747 in validation).
• Elevated cfDNA levels within 48 hours of ECMO initiation were strongly associated with mortality.
• cfDNA showed a positive linear association with the risk of limb ischemia (AUC 0.75).

Conclusions:

• cfDNA, alongside MAP and lactate, is a significant predictor of mortality in VA-ECMO patients.
• cfDNA levels are associated with an increased risk of limb ischemia in ECMO patients.
• Further research can explore cfDNA's utility in managing ECMO-related complications.